Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance

Abstract

Medical personnel are a group of people that often encounter infectious agents, leading to greater risk of contracting infectious diseases. Specific prevention of diseases in this group is a priority. The epidemiological effectiveness of COVID-19 prevention in the group of medical workers due to the emergence of new variants of concern of the SARS-CoV-2 virus has not been studied in sufficient depth. We conducted a study of the effectiveness of vaccine use to protect medical workers at a large medical center for obstetrics and gynecology in Moscow. Sputnik V and Sputnik Light were the main vaccines used for the prevention of COVID-19. The vaccines are based on a variant of the S-protein of the SARS-CoV-2 virus, with adenovirus serotypes 5 and 26 as the vector for delivery. Vaccination of employees occurred during the period in which the Delta variant was spreading. The overall epidemiological effectiveness was 81.7% (73.1–87.6%) during the period in which the Delta variant was dominant. During the period from the beginning of vaccination (26 November 2020) until 8 February 2022, the overall effectiveness was 89.1% (86.9–91.0%). As expected, the highest effectiveness during this period was obtained in the group that received the third and fourth doses—96.5% (75.0–99.5%). The severity of COVID-19 in the vaccinated group was significantly lower than in the unvaccinated group.

An assessment of the strategy and status of COVID-19 vaccination in India

“…Indian pharmaceutical giant Dr. Reddy made a deal with phase 2/3 human trials in India of Russia's Sputnik V vaccine and produced 100 million doses [42]. The study suggests that both Sputnik V and Sputnik Light are effective against SARS-CoV2 delta variant [43,44].…”

“…Both seropositive and seronegative participants showed strong humoral (enhanced neutralizing antibody response) and cellular immune response (increased antigen-specific T cell proliferation, production of IFNγproducing cells, and their cytokine secretion) upon vaccination [54]. Sputnik Light is also proven to be effective against the Delta variant of coronavirus [43,44].…”

An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

“…It uses a heterologous recombinant adenovirus approach with Ad26 and Ad5 as vectors for the expression of the S protein. This vaccine was safe with 91.6% efficacy and generated a good humoral and cell-mediated immunity against SARS-CoV-2, including the omicron variants [78][79][80][81]. Sputnik light is another COVID-19 vaccine by Gamaleya where the S protein is expressed by the Ad5 vector.…”

“…Sputnik light is another COVID-19 vaccine by Gamaleya where the S protein is expressed by the Ad5 vector. This vaccine has an efficacy of 79.4% and has proven effective against all variants including delta and omicron [81][82][83]. The Ad26.COV2.S or Jcovden was developed by Janssen (Beerse, Belgium), the pharmaceutical wing of Johnson & Johnson (JNJ).…”

Impact of vaccination against the novel coronavirus infection (COVID-19) with Sputnik V on mortality during the delta variant surge

“…The protective effect of Sputnik V against death from COVID-19 was demonstrated in a large study in Hungary; however, this occurred before the period of delta variant dominance [9] . Sputnik V has been shown to be effective against this variant in a small study among medical professionals [14] . However, its effect on mortality did not study in that research.…”